Intermune Inc: (NASD: ITMN)

$9.99

-0.31 (-3.01%)

Volume 1,536,397

May 17 04:00 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		9.94 - 10.54
	
		52wk Low - High
		7.21 - 12.77
	
		Previous Close
		10.30
	
		Avg. Volume
		1,436,722
	
		Industry
		MED-BIOMED/GENE
	
		Market Cap
		815.19 M
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		2.26
	
		PE (Forward)
		0.00
	
		Current Year Est.
		-2.75
	
		Quarterly Earnings ESP 
		0.00%
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		91 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/13/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            PE (Forward)
                            NA
                        
                            PEG Ratio
                            NA
                        
                            Current Year Est.
                            -2.75
                        
                            Current Quarter Estimate
                            -0.69
                        
                            Most Accurate Estimate
                            -0.69
                        
                            Earnings ESP 
                            0.00%
                        
                            Next Earnings Report Date
                            07-22-2013
                        
                            EPS Last Year
                            -3.05
                        
                            Expected Earnings Growth
                            NA
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
InterMune Pharmaceuticals Inc. develops and commercializes innovative products for the treatment of serious pulmonary and infectious diseases and congenital disorders.  The company markets ACTIMMUNE for chronic granulomatous disease and osteopetrosis.  The company has active development programs underway for the other disease areas, several of which are in mid-or advanced-stage human testing, known as clinical trials.   
Full ITMN Company Report

        
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
ITMN Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	-0.69	-0.70	-2.75	-1.94
Number of Estimates	10	10	11	11
Low Estimate	-0.76	-0.74	-2.95	-2.34
High Estimate	-0.60	-0.62	-2.52	NA
Year Ago EPS	-0.78	-0.70	-2.82	-2.75
EPS Growth	11.41%	0.00%	2.51%	29.50%

More ITMN Estimates

Average Earnings Estimates for ITMN

EPS Growth for ITMN

Industry Analysis

Name	Symbol	Previous Close
INTERMUNE INC	ITMN	9.99
AETERNA ZENTARS	AEZS	2.10
ANIKA THERAPEUT	ANIK	14.40
GENTIUM SPA-ADR	GENT	8.87
AASTROM BIOSCI	ASTM	0.57
ACHILLION PHARM	ACHN	7.77
ADDEX THERA LTD	ADDXF	6.94
AFFYMAX INC	AFFY	1.33
ALEXION PHARMA	ALXN	102.90
ALKERMES INC	ALKS	31.69

Sector:Medical>> Industry:MED-BIOMED/GENE

COMPARE TICKER vs. Its Peers

Zacks Commentary

InterMune Cuts Loss, Affirms View

Apr 25, 2013

NICE News for InterMune

Mar 22, 2013

Wider Loss at InterMune

Feb 22, 2013

InterMune Prices Public Offerings

Jan 18, 2013

InterMune Inc., Novartis, Celgene Corporation, Targacept Inc. and Agenus Inc. highlighted in Zacks Analyst Blog

Jan 17, 2013

InterMune to Raise Funds

Jan 16, 2013

InterMune Reports 4Q Esbriet Sales

Jan 04, 2013

Loss at ITMN Narrower than Expected

Nov 08, 2012

More ITMN Zacks Commentary

Financials

EPS TTM	-3.05
Sales	26
Net Income	-153
Price/Earnings	NA
Price/Book	4.95
Price/Cash Flow	NA
Price/Sales	25.62

More ITMN Financials

News

Stock Investors Sell Off Shares of InterMune, Down 1.9% - Financial News Network Online - Market Movers

May 17, 2013

Critical Alerts For Pfizer, CBS, International Paper, Youku.com, and InterMune Released By InvestorsObserver - Pr Newswire

May 14, 2013

InterMune Shares Climbing Higher, Up 1.8% - Financial News Network Online - Market Movers

May 14, 2013

InterMune Crosses Above its 10-day MA (ITMN) - Financial News Network Online - Moving Average Crossovers

May 10, 2013

Shares of InterMune Receive a Boost, Up 3.7% - Financial News Network Online - Market Movers

May 10, 2013

InterMune Shares Climbing Higher, Up 1.9% - Financial News Network Online - Market Movers

May 6, 2013

2 Biotechs To Avoid, 1 To Buy - TheMotleyFool

May 3, 2013

InterMune reports higher Q1 net loss, provides guidance for 2013 - Datamonitor

May 3, 2013

See All News Stories on ITMN

Broker Recommendations

Current ABR	1.38
ABR (Last Week)	1.38
# of recs in ABR	13
Average Target Price	14.50
Industry Rank by ABR	91 out of 265
Rank in Industry	36 out of 155

More ITMN Broker Recommendations

Day Low - High	9.94 - 10.54
52wk Low - High	7.21 - 12.77
Previous Close	10.30
Avg. Volume	1,436,722
Industry	MED-BIOMED/GENE
Market Cap	815.19 M
Div - Yield	0.00 - 0.00
Beta	2.26
PE (Forward)	0.00
Current Year Est.	-2.75
Quarterly Earnings ESP	0.00%

PE (Forward)	NA
PEG Ratio	NA
Current Year Est.	-2.75
Current Quarter Estimate	-0.69
Most Accurate Estimate	-0.69
Earnings ESP	0.00%
Next Earnings Report Date	07-22-2013
EPS Last Year	-3.05
Expected Earnings Growth	NA

Username: Password:

Remember me [?]

Intermune Inc: (NASD: ITMN)

$9.99

-0.31 (-3.01%)

Volume 1,536,397

May 17 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description